Efficacy and safety of intrathecal dexamethasone combined with isoniazid in the treatment of tuberculous meningitis: a meta-analysis
Authors:
Open Access
- 10 June 2024
- journal article
- research article
- Published by Springer Nature in BMC Neurology
- Vol. 24 (1) , 1-14
Abstract
Background: The treatment regimen for tuberculous meningitis (TBM) remains unclear and requires optimization. There are some reports on successful adjunct intrathecal dexamethasone and isoniazid (IDI) treatment strategies for TBM, however, there is equivocal evidence on their efficacy and safety. Methods: A comprehensive search of English and Chinese databases was conducted from inception to February 2024. A meta-analysis was performed on randomized controlled trials (RCTs) estimating the effects of adjunct IDI on conventional anti-TB (C anti-TB) treatments or C anti-TB alone. Efficacy, adverse reaction rate, cerebrospinal fluid (CSF) leukocytes, and CSF protein were used as primary outcome indicators. CSF glucose, CSF chlorides, CSF pressure, recovery time for laboratory indicators and recovery time for clinical symptoms were used as secondary outcome indicators. Results: A total of 17 studies involving 1360 (IDI group vs. C anti-TB group: 392 vs. 372; higher-dose IDI group vs. lower-dose IDI group: 319 vs. 277) patients were included in our analysis. Efficacy was significantly higher (RR 1.3, 95% CI 1.2-1.4, P < 0.001) and adverse reaction rate was significantly lower in the IDI groups (RR 0.59, 95% CI 0.37-0.92, P = 0.021). Furthermore, CSF leukocytes (WMD - 29.33, 95% CI [- 40.64 to-18.02], P < 0.001) and CSF protein (WMD - 0.79, 95%CI [-0.96 to-0.61], P < 0.001) were significantly lower in the IDI groups. Recovery time indicators were all shorter in the IDI groups, fever (SMD - 2.45, 95% CI [-3.55 to-1.35], P < 0.001), coma (SMD-3.75, 95% CI [-4.33 to-3.17], P < 0.001), and headache (SMD - 3.06, 95% CI [- 4.05 to-2.07], P < 0.001), respectively. Higher-dose IDI was more effective than lower-dose IDI (RR 1.23, 95% CI 1.14-1.33, P < 0.001), with no significant difference in adverse reaction rate between the two (RR 0.82, 95%CI 0.43–1.56, P = 0.544). Conclusion: Adjunct IDI with C anti-TB can enhance therapeutic outcomes and reduce adverse reaction rate in adult TBM patients, with higher-dose IDI showing superior efficacy. These findings highlight the potential of IDI as an adjunctive therapy in TBM management. However, more high-quality RCTs from more regions should be conducted to support our results. Trial registration: Retrospectively registered in PROSPERO https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023388860.Keywords
This publication has 34 references indexed in Scilit:
- Tuberculous meningitis: more questions, still too few answersThe Lancet Neurology, 2013
- Tuberculous Meningitis: Diagnosis and Treatment OverviewTuberculosis Research and Treatment, 2011
- British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and childrenJournal of Infection, 2009
- Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement2009
- A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpointsStatistics in Medicine, 2005
- Dexamethasone for the Treatment of Tuberculous Meningitis in Adolescents and AdultsNew England Journal of Medicine, 2004
- Bias in meta-analysis detected by a simple, graphical testBMJ, 1997
- Intraventricular rifampicin in severe tuberculous meningo-encephalitisEuropean Respiratory Journal, 1992
- Intraventricular administration of rifampin for tuberculous meningitisJournal of Neurology, 1981
- Mixed pneumococcal and tuberculous meningitis.Archives of Disease in Childhood, 1974